We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




World’s First Test Detects Diabetics at Risk of Kidney Disease before Symptoms Appear

By LabMedica International staff writers
Posted on 19 Jan 2023

Millions of people with diabetes live with chronic kidney disease and have a poorer chance of survival. More...

The current standard assays used in clinics depend on assessing kidney function and the extent of kidney damage caused by diabetes. However, there are usually no symptoms during the early stages of the disease. There have been huge advances in genetic testing, although risk genes for diabetic kidney disease (DKD) have yet to be identified. Now, an international team of researchers have identified the genetic markers for people with diabetes who are at a risk of developing kidney disease. This paves the way for the development of a test that could identify adults with Type 1 diabetes who are at a risk of kidney disease before they show any symptoms, enabling the introduction of early-stage interventions by doctors.

In the world’s first international study led by Monash University (Melbourne, Australia), the researchers tested the genes in 1017 Scandinavian and Asian diabetes cohorts and examined a process called methylation, in which a small molecule called a methyl group gets added to DNA. The findings from the largest-ever international study on Type 1 diabetes revealed that “important clues that reduced DNA methylation is closely associated with the increased risk of diabetes relate kidney disease,” said Professor Sam El-Osta, from Central Clinical School, Human Epigenetics team at the Department of Diabetes at Monash University. “These discoveries will influence how we screen patients with diabetes and improve risk stratification, disease prediction and diagnosis.”

“The team at Monash University's Central Clinical School using innovative sequencing techniques developed gene methylation risk scores that are tightly associated with early detection and the development of diabetic kidney disease,” added Professor El-Osta. “Scientists searching for blood-based biomarkers in diabetes cohorts originating from Finland, Denmark, Hong Kong and Thailand, found surprising commonality in gene methylation risk scores. They note that the innovative sequencing technologies developed using the internal collaboration revealed missing methylation data that was ultimately used to develop a predictive test for diabetic kidney disease.”

“As far as technological advancements in methods are concerned, epigenetic testing is going to be the new standard for early detection and DKD care,” explained Professor El-Osta. “Renal biopsies are difficult to procure and the novel blood-based test means the test can be readily available and used in remote areas with the added advantage of being more stable than methods measuring other biological indices.”


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.